JP6322280B2 - Ｓ−１００阻害薬として有用なｎ−（ヘテロアリール）スルホンアミド誘導体 - Google Patents

Ｓ−１００阻害薬として有用なｎ−（ヘテロアリール）スルホンアミド誘導体 Download PDF

Info

Publication number
JP6322280B2
JP6322280B2 JP2016513346A JP2016513346A JP6322280B2 JP 6322280 B2 JP6322280 B2 JP 6322280B2 JP 2016513346 A JP2016513346 A JP 2016513346A JP 2016513346 A JP2016513346 A JP 2016513346A JP 6322280 B2 JP6322280 B2 JP 6322280B2
Authority
JP
Japan
Prior art keywords
chloro
hydroxypyridin
sulfonamide
methanesulfonamide
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016513346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518428A (ja
JP2016518428A5 (pt
Inventor
フリトゾン，インジェラ
リバーグ，デヴィッド
イースト，ステファン
マッキノン，コリン
プレヴォスト，ナターシャ
Original Assignee
アクティブ バイオテック エイビー
アクティブ バイオテック エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティブ バイオテック エイビー, アクティブ バイオテック エイビー filed Critical アクティブ バイオテック エイビー
Publication of JP2016518428A publication Critical patent/JP2016518428A/ja
Publication of JP2016518428A5 publication Critical patent/JP2016518428A5/ja
Application granted granted Critical
Publication of JP6322280B2 publication Critical patent/JP6322280B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016513346A 2013-05-14 2014-05-14 Ｓ−１００阻害薬として有用なｎ−（ヘテロアリール）スルホンアミド誘導体 Active JP6322280B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13167680.1 2013-05-14
EP13167680 2013-05-14
PCT/EP2014/059829 WO2014184234A1 (en) 2013-05-14 2014-05-14 N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors

Publications (3)

Publication Number Publication Date
JP2016518428A JP2016518428A (ja) 2016-06-23
JP2016518428A5 JP2016518428A5 (pt) 2017-06-22
JP6322280B2 true JP6322280B2 (ja) 2018-05-09

Family

ID=48366235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513346A Active JP6322280B2 (ja) 2013-05-14 2014-05-14 Ｓ−１００阻害薬として有用なｎ−（ヘテロアリール）スルホンアミド誘導体

Country Status (13)

Country Link
US (2) US9873687B2 (pt)
EP (1) EP2925743B1 (pt)
JP (1) JP6322280B2 (pt)
KR (1) KR20160006717A (pt)
CN (1) CN105377837B (pt)
AU (1) AU2014267360B2 (pt)
BR (1) BR112015027395A2 (pt)
CA (1) CA2912313A1 (pt)
EA (1) EA028512B1 (pt)
ES (1) ES2563902T3 (pt)
HK (1) HK1213254A1 (pt)
MX (1) MX360455B (pt)
WO (1) WO2014184234A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260692A1 (en) * 2019-06-28 2020-12-30 Calprotect Ab Compound for treatment of acute inflammation in the myocardium
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法
CN112480106B (zh) * 2020-11-17 2022-09-02 南京海纳医药科技股份有限公司 一种马来酸阿伐曲泊帕杂质的制备方法
CN115974772B (zh) * 2023-01-05 2024-06-14 山东铂源药业股份有限公司 一种利用微通道反应器制备吡啶-3-磺酰氯的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313806A (en) 1963-07-01 1967-04-11 Sumitomo Chemical Co Sulfanilylaminopyridazinone derivatives and method for their production
WO1997010214A1 (fr) * 1995-09-14 1997-03-20 Shionogi & Co., Ltd. Nouveaux derives d'acide phenylacetique et compositions medicinales les contenant
EP1458715B1 (en) * 2001-12-18 2005-12-07 AstraZeneca AB Novel compounds
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
US20060004085A1 (en) * 2002-03-29 2006-01-05 University Of Maryland , Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
NZ565749A (en) 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
US9040538B2 (en) 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
EP2521551A4 (en) 2010-01-06 2013-08-21 Errico Joseph P METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
EP2560655B1 (en) * 2010-04-21 2016-08-24 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2616450B1 (en) * 2010-09-17 2018-05-02 Kancera AB Sulfonamide compounds

Also Published As

Publication number Publication date
WO2014184234A1 (en) 2014-11-20
CA2912313A1 (en) 2014-11-20
ES2563902T3 (es) 2016-03-16
EA028512B1 (ru) 2017-11-30
AU2014267360A1 (en) 2015-12-17
KR20160006717A (ko) 2016-01-19
US9873687B2 (en) 2018-01-23
MX2015015741A (es) 2016-03-16
EA201592166A1 (ru) 2016-05-31
AU2014267360B2 (en) 2018-07-05
US10125125B2 (en) 2018-11-13
JP2016518428A (ja) 2016-06-23
CN105377837A (zh) 2016-03-02
HK1213254A1 (zh) 2016-06-30
CN105377837B (zh) 2017-08-04
MX360455B (es) 2018-11-01
EP2925743B1 (en) 2016-02-03
EP2925743A1 (en) 2015-10-07
BR112015027395A2 (pt) 2017-08-29
US20160115158A1 (en) 2016-04-28
US20180155330A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
JP7026196B2 (ja) Ｒｅｔの阻害剤
TWI795381B (zh) 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP2021042243A (ja) アリール置換またはヘテロアリール置換ベンゼン化合物
TW530047B (en) Corticotropin releasing factor antagonists
ES2632954T3 (es) Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
JP2023002840A (ja) Ｐｄｋ１インヒビターとして有用な複素環式化合物
US10125125B2 (en) N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
CA2655128A1 (en) Quinoline compounds and methods of use
JP5575799B2 (ja) ７−フェノキシクロマンカルボン酸誘導体
US20070213325A1 (en) Multi-cyclic compound and method of use
KR102383938B1 (ko) 신규한 매크로시클릭 화합물
JP6990196B2 (ja) ピリミジン誘導体
EA026729B1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
CN103012399A (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
ES2298853T3 (es) Aroilfuranos y aroiltiofenos apropiados para el tratamiento del cancer.
KR20230116795A (ko) 피리미딘 화합물, 조성물, 및 이들의 의약적 응용
WO2018214866A9 (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
JP6969800B2 (ja) 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
TW202144333A (zh) 醯胺類化合物及其用途
AU2015261775A1 (en) Novel compounds useful as S100-inhibitors
WO2023143135A1 (zh) 一种喹唑啉衍生物及其用途
IL270066B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
TW200812979A (en) Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2024131938A1 (zh) 喹唑啉类化合物及其用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180406

R150 Certificate of patent or registration of utility model

Ref document number: 6322280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250